Cash boost for SpectRx' cervical cancer detector:
This article was originally published in Clinica
Executive Summary
SpectRx is to accelerate its programme to develop a non-invasive cervical cancer detection device, after receiving a $1.4m grant award from the US National Cancer Institute. The grant will be primarily used to help fund the pivotal clinical trials necessary for approval to market the biophotonic device in the US. The Norcross, Georgia firm said that the trials would start within 90 days.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.